Profil Institute believes in partnering with companies with innovative methodologies or technologies to advance metabolic research, aspiring to bring better treatments and therapeutics to the patient faster.
Profil Institute’s partners include:
Mercodia is a world-leading developer, manufacturer and distributor of high quality immunoassay kits. We specialize in ELISA assays for clinical as well as research applications, notably within diabetes, obesity and cardiovascular disease. We offer assays applicable in both human and animal models.
Mercodia – When accuracy matters.
bd@mercodia.com www.mercodia.se
KineMed is a leading provider of stable isotope based in vivo assays for investigating diabetes, obesity and cardiovascular diseases. KineMed offers partners a complete range of service from consulting on study design and tracer method selection, to full analytical and mass spectrometry support, data analysis, and interpretation for both preclinical and clinical studies.
www.kinemed.com
Lipomics provides metabolite profiling, biomarker discovery and metabolism consultation services to industry. Our technology is used to develop an understanding of metabolism in disease, the effects of drugs or foods on metabolism and for identifying biomarkers for use in clinical trials and as commercial products. Scientists at Lipomics are trained biochemists and statisticians with years of experience in interpreting metabolic profiles and in developing diagnostics.
www.lipomics.com
Rosa creates robust mathematical models to predict drug effects and trial outcomes from preclinical through clinical development by simulating disease physiology, drug action and patient variability. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs.
www.rosaandco.com
